The REVERT IPF Phase 2 trial showed TTI-101 reduced fibrosis and inflammation markers versus placebo, with a manageable safety profile but higher discontinuation rates, especially when combined with nintedanib. Placebo overperformance and variability limited efficacy conclusions.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.